American Research Journal of Biomedical Engineering

C. Τsompos1*, C. Panoulis2, K Τοutouzas3, A. Triantafyllou4, CG. Ζografos5, K.Tsarea6, M. Karamperi7, A. Papalois8

Aim: This study calculated the effects on creatine phosphokinase (CPK) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment. Materials and Methods: The 2 main experimental endpoints at which the serum CPK levels (CPKl) were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration. Results: The first preliminary study of Epo presented a non significant hyperkinase mice ffect by 2.08%+2.77% (p-value=0.4430). The second preliminary study of U-74389G presented a significant hyperkinasemic effect by 8.52%+4.35% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that L is 4.09626-fold [4.092989 - 4.099534] more hyperkinasemic than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G ascribe 4.09626-fold more hyperkinasemic effects than Epo (p-value=0.0000)

Constantinos Tsompos1*, Constantinos Panoulis2, Konstantinos Toutouzas3 Aggeliki Triantafyllou4, George C. Zografos5, Kalliopi Tsarea6, Maria Karamperi7 Apostolos Papalois8

Aim: This study co-evaluated the 2 quoted histologic variables after the erythropoietin (Epo) administration. The calculation was based on the results of 2 preliminary studies, each one evaluating a respective histologic variable of ovarian epithelium karyorrhexis (OK) or oophoritis (OI) in an induced ischemia reperfusion animal experiment. Materials and Methods: The 2 main experimental endpoints at which the OK and OI scores were evaluated was the 60th reperfusion min(for the groups A and C) and the 120th reperfusion min (for the groups B and D). Specially, the groups A and B were processed without drugs, whereas the groups C and D after Epo administration. Results: The first preliminary study showed that Eponon significantly recessed the ovarian epithelium karyorrhexis (OK) within the “without lesions alterations” grade by 0.0818182 [-0.2159977 - 0.0523614] (p-value=0.2246)1. However, the second preliminary study showed that Epo significantly enhanced oophoritis (OI) within the “without lesions alterations” grade by 0.1363636 [0.0421443 - 0.230583] (p-value=0.0057)2. These 2 studies were co-evaluated since they came from the same experimental setting. This study investigated the combined diagnostic value of both variables together. Conclusions: Epo has a hardly deteriorating potency of these histologic parameters within the “without lesions alterations” grade by 0.0272727 [-0.0556778 - +0.1102233] (p-value=0.5097) since they were co-evaluated together.